| 2023-03-10 |
详情>>
内部人交易：
Mehra Uneek等共交易15笔
|
| 2023-01-26 |
详情>>
股本变动：
变动后总股本9723.53万股
|
| 2023-01-26 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.29美元,归母净利润-1.24亿美元,同比去年增长15.14%
|
| 2023-01-23 |
股东大会：
将于2023-03-01召开股东大会
会议内容 ▼▲
- 1.A proposal to adopt and approve an Agreement and Plan of Merger, dated as of October 23, 2022 (as it may be amended from time to time in accordance with its terms, the “Merger Agreement”) and a related Statutory Merger Agreement (the “Statutory Merger Agreement”), by and among Myovant, Sumitovant Biopharma Ltd., a Bermuda exempted company limited by shares (“Sumitovant”), Zeus Sciences Ltd., a Bermuda exempted company limited by shares and a wholly owned subsidiary of Sumitovant (“Merger Sub”) and, solely with respect to Article IX and Annex A of the Merger Agreement, Sumitomo Pharma Co., Ltd., a company organized under the laws of Japan (“SMP”), and the transactions contemplated by the Merger Agreement and the Statutory Merger Agreement, including a merger, pursuant to which Merger Sub will merge with and into Myovant (the “Merger”), with Myovant continuing as the surviving company following the Merger as a wholly owned subsidiary of Sumitovant (the “Merger Proposal”);
2.A non-binding, advisory proposal to approve specified compensation that may become payable to Myovant’s named executive officers in connection with the completion of the Merger (the “Compensation Proposal”);
3.A proposal to approve an adjournment of the special general meeting, if necessary or appropriate (as determined by Myovant after consultation in good faith with Sumitovant), to solicit additional proxies if there are insufficient votes at the time of the special general meeting to approve the Merger Proposal (the “Adjournment Proposal”).
|
| 2022-10-26 |
详情>>
业绩披露：
2023年中报每股收益-0.7美元,归母净利润-6685.8万美元,同比去年增长19.69%
|
| 2022-10-26 |
财报披露：
美东时间 2022-10-26 盘后发布财报
|
| 2022-07-28 |
股东大会：
将于2022-10-21召开股东大会
会议内容 ▼▲
- 1.To elect the Board’s seven nominees for director, Terrie Curran, Mark Guinan, Adele Gulfo, David Marek, Shigeyuki Nishinaka, Myrtle Potter, and Nancy Valente, M.D., to serve as directors for a one-year term.
2.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending March 31, 2023, to appoint Ernst & Young LLP as our auditor for statutory purposes under the Bermuda Companies Act 1981, as amended, for our fiscal year ending March 31, 2023, and to authorize the Board of Directors, through the Audit Committee, to set the remuneration for Ernst & Young LLP as our auditor for our fiscal year ending March 31, 2023.
3.To approve, on an advisory basis, the compensation of our named executive officers, as described in the Proxy Statement accompanying this Notice.
4.To conduct any other business properly brought before the Annual Meeting.
|
| 2022-07-27 |
详情>>
业绩披露：
2023年一季报每股收益-0.22美元,归母净利润-2123.9万美元,同比去年增长65.55%
|
| 2022-05-11 |
详情>>
业绩披露：
2020年年报每股收益-3.37美元,归母净利润-2.89亿美元,同比去年增长-5.64%
|
| 2022-05-11 |
详情>>
业绩披露：
2022年年报每股收益-2.22美元,归母净利润-2.06亿美元,同比去年增长19.27%
|
| 2022-01-26 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-1.59美元,归母净利润-1.47亿美元,同比去年增长15.58%
|
| 2021-10-26 |
详情>>
业绩披露：
2021年中报每股收益-1.12美元,归母净利润-9992.2万美元,同比去年增长27.84%
|
| 2021-10-26 |
详情>>
业绩披露：
2022年中报每股收益-0.9美元,归母净利润-8325.1万美元,同比去年增长16.68%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-07-28 |
股东大会：
将于2021-11-05召开股东大会
会议内容 ▼▲
- 1.To elect the Board’s six nominees for director, Terrie Curran, Mark Guinan, Adele Gulfo, David Marek, Hiroshi Nomura, and Myrtle Potter to serve as directors for a one-year term.
2.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending March 31, 2022, to appoint Ernst & Young LLP as our auditor for statutory purposes under the Bermuda Companies Act 1981, as amended, for our fiscal year ending March 31, 2022, and to authorize the Board of Directors, through the Audit Committee, to set the remuneration for Ernst & Young LLP as our auditor for our fiscal year ending March 31, 2022.
3.To approve, on an advisory basis, the compensation of our named executive officers, as described in the Proxy Statement accompanying this Notice.
4.To conduct any other business properly brought before the Annual Meeting.
|
| 2021-07-28 |
详情>>
业绩披露：
2022年一季报每股收益-0.67美元,归母净利润-6166万美元,同比去年增长-87.64%
|
| 2021-05-11 |
详情>>
业绩披露：
2021年年报每股收益-2.83美元,归母净利润-2.55亿美元,同比去年增长11.71%
|
| 2021-02-11 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-1.94美元,归母净利润-1.74亿美元,同比去年增长22.45%
|
| 2020-07-24 |
股东大会：
将于2020-09-15召开股东大会
会议内容 ▼▲
- 1.To elect the Board’s seven nominees for director, Terrie Curran, Mark Guinan, Adele Gulfo, Hiroshi Nomura, Myrtle Potter, Kathleen Sebelius and Lynn Seely, M.D., to serve as directors for a one-year term.
2.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending March 31, 2021, to appoint Ernst & Young LLP as our auditor for statutory purposes under the Bermuda Companies Act 1981, as amended, for our fiscal year ending March 31, 2021, and to authorize the Board of Directors, through the Audit Committee, to set the remuneration for Ernst & Young LLP as our auditor for our fiscal year ending March 31, 2021.
3.To approve, on an advisory basis, the compensation of our named executive officers, as described in the Proxy Statement accompanying this Notice.
|
| 2019-07-25 |
股东大会：
将于2019-08-23召开股东大会
会议内容 ▼▲
- 1.To elect the Board’s seven nominees for director, Terrie Curran, Mark Guinan, Myrtle Potter, Vivek Ramaswamy, Kathleen Sebelius, Lynn Seely, M.D., and Frank Torti, M.D. to serve as directors for a one-year term.
2.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending March 31, 2020, to appoint Ernst & Young LLP as our auditor for statutory purposes under the Bermuda Companies Act 1981, as amended, for our fiscal year ending March 31, 2020, and to authorize the Board of Directors, through the Audit Committee, to set the remuneration for Ernst & Young LLP as our auditor for our fiscal year ending March 31, 2020.
3.To approve, on an advisory basis, the compensation of our named executive officers, as described in the Proxy Statement accompanying this Notice.
4.To indicate, on an advisory basis, the preferred frequency of future advisory votes on the compensation of our named executive officers.
|
| 2018-07-25 |
股东大会：
将于2018-08-31召开股东大会
会议内容 ▼▲
- 1. To elect the Board’s seven nominees for director, Mark Altmeyer, Terrie Curran, Mark Guinan, Keith Manchester, M.D., Vivek Ramaswamy, Kathleen Sebelius, and Lynn Seely, M.D. to serve as directors for a one year term.
2. To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending March 31, 2019, to appoint Ernst & Young LLP as our auditor for statutory purposes under the Bermuda Companies Act 1981, as amended, for our fiscal year ending March 31, 2019, and to authorize the Board of Directors, through the Audit Committee, to set the remuneration for Ernst & Young LLP as our auditor for our fiscal year ending March 31, 2019.
|
| 2018-01-22 |
股东大会：
将于2018-02-09召开股东大会
会议内容 ▼▲
- 1.Declassify the Board of Directors, or the Board, so that directors are elected annually rather than for staggered three-year terms;
2.Modify shareholder proposal and nomination procedures;
3.Eliminate all supermajority voting requirements;
4.Modify certain director removal and vacancy requirements to allow eligible shareholders to replace directors without cause at a special general meeting;
5.Revise certain other provisions in the Existing Bye-laws.
|
| 2017-07-21 |
股东大会：
将于2017-08-18召开股东大会
会议内容 ▼▲
- 1.To elect the Board’s three nominees for director, Mark Altmeyer, Terrie Curran, and Keith Manchester, M.D., to serve as Class I Directors until our 2020 Annual General Meeting of Shareholders and until their successors are duly elected.
2.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending March 31, 2018, to appoint Ernst & Young LLP as our auditor for statutory purposes under the Bermuda Companies Act 1981, as amended, for our fiscal year ending March 31, 2018 and to authorize the Board of Directors, through the Audit Committee, to set the remuneration for Ernst & Young LLP as our auditor for our fiscal year ending March 31, 2018.
3.To conduct any other business properly brought before the Annual Meeting.
|